title: Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
abstract: Advancements in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice. Understanding how and when to use this technology to guide pharmacotherapy used to treat psychiatric and neurological (neuropsychiatric) conditions remains a challenge for many clinicians. Currently, guidelines exist to assist clinicians in the use of existing genetic information for drug selection and/or dosing for the tricyclic antidepressants, carbamazepine, and phenytoin. Additional language in the product labeling suggests that genetic information may also be useful for determining the starting and target doses, as well as drug interaction potential, for a number of other drugs. In this review, we outline the current status of pharmacogenomic testing for neuropsychiatric drugs as it pertains to information contained in drug labeling, consensus guidelines, and test panels, as well as considerations related to obtaining tests for patients.
authors: Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois.
authors: Katarzyna
authors: K
authors: Drozda
authors: Daniel J
authors: DJ
authors: Müller
authors: Jeffrey R
authors: JR
authors: Bishop
mesh_terms: D002491:Central Nervous System Agents / Q000627:therapeutic use; D004347:Drug Interactions; D004348:Drug Labeling; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D017410:Practice Guidelines as Topic; D011619:Psychotropic Drugs / Q000627:therapeutic use*
chemical_list: D002491:Central Nervous System Agents; D011619:Psychotropic Drugs
keywords: CYP2C19; CYP2D6; Stevens-Johnson syndrome; antidepressants; antipsychotics; pharmacogenetic testing; pharmacogenetics; pharmacogenomics